Overview

• Researchers from Chalmers University and Harvard University analyzed over 200,000 UK Biobank participants to validate the predictive power of apoB and lipoprotein(a) markers.
• The study found that apoB particle count is the most accurate single measure for assessing heart disease risk, outperforming traditional cholesterol tests.
• Lipoprotein(a), a genetically determined marker, was identified as a critical complement to apoB for a comprehensive risk profile.
• Standard cholesterol tests may underestimate risk in one in 12 patients, potentially missing high-risk individuals who could benefit from early intervention.
• Both apoB and lipoprotein(a) tests are commercially available, low-cost, and positioned for integration into routine clinical practice to improve cardiovascular outcomes.